Blueprint Medicines Corp (BPMC)
2025-03-31 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenue | 149,413 | 128,184 | 138,157 | |
| Gain (loss) on extinguishment of debt | - | 173,700 | 18 | |
| Equity investment gain | 50,039 | - | - | |
| Other income, net | 461 | 587 | -1 | |
| Interest expense, net | -8,129 | -7,616 | -6,864 | |
| Total other income, net | 42,371 | -7,029 | -6,847 | |
| Collaboration profit (loss) sharing | - | - | - | |
| Selling, general and administrative | 95,807 | 89,926 | 89,339 | |
| Research and development | 91,890 | 85,300 | 84,270 | |
| Cost of sales | 2,802 | 1,932 | 7,593 | |
| Total cost and operating expenses | 190,499 | 177,158 | 181,202 | |
| Income before income taxes | 1,285 | -56,003 | -49,892 | |
| Income tax expense | 789 | 273 | 102 | |
| Net income | 496 | -56,276 | -49,994 | |
| Currency translation adjustments | -143 | -119 | -96 | |
| Unrealized gain (loss) on available-for-sale investments | 457 | 2,939 | 53 | |
| Comprehensive income | 810 | -53,456 | -50,037 | |
| Basic eps | 0.01 | -0.89 | -0.8 | |
| Diluted eps | 0.01 | -0.89 | -0.8 | |
| Basic average shares | 64,096,000 | 63,381,000 | 62,854,000 | |
| Diluted average shares | 66,526,000 | 63,381,000 | 62,854,000 | |